News
We send the latest information from SMC Laboratories.
Published papers with IPF model
We would like to share with you some examples of studies that our clients have often asked us about using the IPF model. CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology company developing mitochondria-based therapeutics also announced interesting data with our IPF model at the American Thoracic Society’s Virtual 2020 Conference. The ePoster presents…
Why is Chronic Kidney Disease so hard to research?
Between 9 – 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, how can we develop more effective therapies for this underserved population? –What is chronic kidney disease? CKD is a persistent loss of kidney function and structural abnormalities that are assessed using markers of kidney damage and histological…
What is proteinuria’s role in evaluating the progression of CKD?
When discussing our mouse models for chronic kidney disease (CKD), we are often asked about proteinuria as a urinary marker of kidney damage. As an important marker used in clinical trials, it's also an important endpoint to look at in non-clinical research as well. Proteinuria data in the Adriamycin model The graph above shows…
What is the relationship between NASH and Liver Cancer?
You may know that liver cancer is one of the most prevalent cancers, but do you know about its relationship with nonalcoholic steatohepatitis (NASH), which is rapidly increasing as a liver disease? The existence of NAFLD-related HCC, which we at SMC Laboratories, Inc. have been focusing on for more than 10 years, is now being…
SMC attend BIO Partnering at JPM Week!
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One Partnering event next week from Monday, January 10th to Friday, January 14th. If you are interested in attending BIO Partnering, please visit their website for more information on the event and how to register.
Long-COVID, COVID-19 variants, and the emergence of pulmonary fibrosis in recovered COVID-19 patients
COVID-19 is a virus belonging to the beta-coronavirus class, similar to the virus that causes severe acute respiratory syndrome (SARS). It has been reported that fibrosis could begin to be observed several weeks after infection during the SARS epidemic. In subsequent follow-up studies, more than 20% of SARS survivors at one year later had pulmonary…
Marvel Biosciences has published a press release regarding the MB-207 efficacy evaluation study for liver fibrosis provided by SMC
Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ mouse model. For detail information, see the Marvel's press release. Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash | MARVEL Biotechnology
SMC announces Presentation of New Data at the KDDW 2021
We are pleased to announce the acceptance of our abstracts, “Molecular Pathogenesis of Non-Alcoholic Steatohepatitis (NASH) through the Dysregulation of Metabolic Organ Network in the NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet” and “RNA-Seq Analysis of Liver from NASH-HCC Model Mouse Treated with Streptozotocin-High Fat Diet“—KDDW 2021, to be held from November 18 to 20,…
STZ: Type 1 or Type 2 Diabetes?
When discussing our unique NASH-HCC model STAM with clients, we are so often asked: What type of diabetes does the streptozotocin induce? Since streptozotocin (an N-acetyl-β-D-glucosaminidase inhibitor; STZ) is cytotoxic to pancreatic beta cells, STZ-induced diabetes models are often considered as a model for Type 1 diabetes mellitus (T1D) which is in definition caused…
Reserve a non-clinical pharmacology consultation with us at BioPharm America!
We are joining BioPharm America™ Digital, one of the most famous virtual biotech partnering and education events. This digital event creates opportunities of exchange between executives from pharmaceutical/biotechnology companies of every size and stage, investors, and academic institutions. BioPharm America™ Digital gives opportunity for ventures within the life science realm to be explored through…